RT @NCIDataSci: #CPTAC researchers have produced a resource of global #proteomic and post-translational modifications, whole genome and whole exome, miRNA and totalRNA sequencing, DNA methylation, imaging & clinical information for cancer patients across 10 tumor types. https://proteomics.cancer.gov/news_and_announcements/introducing-suite-pan-cancer-multi-omic-papers-cptac

RT @NCIJBSloan: New resource coming from #CPTAC! It includes #proteomic and post-translational modifications, whole genome and whole exome sequencing, miRNA and totalRNA sequencing, imaging, and clinical information for over 1,000 cancer patients across 10 tumor types. https://proteomics.cancer.gov/news_and_announcements/introducing-suite-pan-cancer-multi-omic-papers-cptac

RT @CellRepMed: ONLINE NOW: A Pan-Cancer multi-omics paper from @theNCI Clinical Proteomic Tumor Analysis Consortium #CPTAC. Deep learning integrates histopathology and proteogenomics at a pan-cancer level. @compproteomics @NYU @ALazarMDPhD @MDAndersonNews #deeplearning #AI #pathology

RT @: #CPTAC pan-cancer papers! Great work by a huge team, identifying the phenotypic consequences of mutation across 10 cancer types. Proteogenomics FTW!
Driver mutations: https://cell.com/cell/fulltext/S0092-8674(23)00780-8…
Protein modifications:

@at In contemporary biotechnology, the limit on how many samples one can include in a discovery experiment is often both financial and temporal. In a big study I was part of a decade ago, each of our 95 samples was separated to fifteen fractions, each requiring 90 minutes on a mass spectrometer. Our million-dollar mass spec was tied up for months!
https://doi.org/10.1038/nature13438
#proteomics #CPTAC